Navigation Links
AIDS Drugs Don't Need Routine Lab Monitoring
Date:12/9/2009

Finding is good news for first-line treatment in Africa, researchers say

WEDNESDAY, Dec. 9 (HealthDay News) -- In a finding that has implications for how the AIDS virus is treated in Africa, new research suggests that antiretroviral drugs can be given without routine monitoring by lab tests.

But tests of immune-system function might still be a good idea to monitor the progression of the disease and guide the second year of treatment, the study authors report.

Patients with HIV, the virus that causes AIDS, often receive drug treatment in Africa without routine laboratory monitoring. In the study, published online Tuesday in advance of publication in a future print issue of The Lancet, researchers tried to determine if that's a bad idea.

They studied 3,316 HIV-positive adults who were assigned to monitoring in both the doctor's office and the laboratory or only in the doctor's office. The patients were studied in Uganda and Zimbabwe.

"The results clearly show that first-line [antiretroviral therapy, or ART] can be delivered safely without routine biochemistry and hematology monitoring for toxic effects, but that routine CD4-cell count monitoring has a small but significant benefit in terms of disease progression and mortality, probably owing to slightly earlier switching to second-line ART," the researchers wrote.

More information

Avert has more about AIDS in Africa.



-- Randy Dotinga



SOURCE: The Lancet, news release, Dec. 9, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Statement of HDMA President and CEO John M. Gray on the Importation of Prescription Drugs
2. Case Western Reserve to receive $19.7m to study tuberculosis treatment drugs
3. OrderOnlineDrugs.com Makes Ordering Drugs Online Safe and Affordable
4. Second-line CML drugs evoke faster response than front-line therapy
5. Hormonal Drugs Cool Hot Flashes From Prostate Cancer Therapy
6. Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD
7. Diabetes Drugs Go Head-to-Head in Study
8. drugstore.com Continues Global Sales Expansion to More Than 3.5 Billion International Consumers
9. China Nepstar Chain Drugstore Reports 92.1% Year-on-Year Increase in Operating Income for Third Quarter 2009
10. Coverage of inexpensive drugs may increase length and quality of life after heart attack
11. Gene increases effectiveness of drugs used to fight cancer and allows reduction in dosage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... , ... The American Board of Quality Assurance and Utilization Review Physicians (ABQAURP) ... Health Care Quality and Management and Patient Safety. , It is with appreciation and ... also to the Health Care Quality and Patient Safety movements. Diplomates and Members lead ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... and the New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April ... , How will the new EU MDR language change the way manufacturers ...
(Date:3/23/2017)... ... , ... “Beyond and Back”: a true-life testimony of tragedy and the miraculous ... Bonetta Rose, a wife, mother and grandmother committed to sharing her many spiritual adventures ... Rose‘s new book presents actual events in the life of her family, which validate ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... the existence of God. “A Respectful Response To Atheist Manifesto” is the creation ... married to his wife, Nancy, for sixty years. He holds graduate degrees from ...
(Date:3/22/2017)... ... March 23, 2017 , ... Death anxiety is unconscious ... profession, author Joy Nugent was inspired to write the book titled “ As Good ... inward desire to make sense of what she was experiencing at the bedside of ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") ... is pleased to announce that its majority-owned subsidiary, ... U.S. Food and Drug Administration (FDA) for the ... tablets in the 12.5 mg and 25 mg ... equivalent of the branded product Xenazine ® ...
(Date:3/23/2017)... ReNeuron reported in December 2016 positive ... stroke patients, despite not meeting the three-month time frame of ... Research Arm Test (ARAT). As a result, the company has ... study in 2017. Beyond CTX, we expect safety and efficacy ... Phase I data from its critical limb ischaemia (CLI) trial. ...
(Date:3/23/2017)... , Mar 23, 2017 The Board ... to the Annual General Meeting, which is to take place on ... 2 in Lund, Sweden . ... Please see the attached notification, which ... Inrikes Tidningar. NeuroVive Pharmaceutical AB (Publ) The Board Of ...
Breaking Medicine Technology: